VIDEO: ‘We should be offering osimertinib’ for EGFR lung cancer
Click Here to Manage Email Alerts
In this interview, Charu Aggarwal, MD, MPH, discusses results from ADAURA trial presented at this year’s ASCO Annual Meeting.
The phase 3 trial assessed the use of osimertinib (Tagrisso, AstraZeneca) in early stage, resected, EGFR-mutated NSCLC.
“We should be offering osimertinib for our patients with at least stage 2 and higher NSCLC if they have an activating EGFR mutation,” Aggarwal, who is the Lesley M. Heisler assistant professor for lung cancer excellence at University of Pennsylvania's Perelman School of Medicine and a HemOnc Today Editorial Board Member, told Healio.
She added that the results highlight the importance of molecular testing and personalizing care in lung cancer patients.
“That was one of the practice-affirming, if not practice-changing, clinical trials [at ASCO],” Aggarwal said.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts